| Literature DB >> 32716943 |
Paola Giuseppina Brambilla1, Michele Polli1, Danitza Pradelli2, Melissa Papa2, Rita Rizzi1, Mara Bagardi1, Claudio Bussadori2.
Abstract
The epidemiology of Congenital Heart Diseases (CHDs) has changed over the past twenty years. This study aimed to evaluate the prevalence of CHDs in the population of dogs recruited in a single referral center (RC); compare the epidemiological features of CHDs in screened breeds (Boxers) versus non-screened (French and English Bulldogs, German Shepherds); investigate the association of breeds with the prevalence of CHDs; determine the popularity and volatility of breeds over a 20-year period; analysed the trends of the most popular breeds in the overall population of new-born dogs registered in the Italian Kennel Club (IKC) from 1st January 1997 to 31st December 2017. The RC's cardiological database was analysed, and 1,779 clinical records were included in a retrospective observation study. Descriptive statistics and frequencies regarding the most representative breeds and CHDs were generated. A logistic regression model was used to analyse the trends of the most common CHDs found in single and in cluster of breeds. The relationship between breed popularity and presence of CHDs was studied. The most common CHDs were Pulmonic Stenosis, Patent Ductus Arteriosus, Subaortic Stenosis, Ventricular Septal Defect, Aortic Stenosis, Tricuspid Dysplasia, Atrial Septal Defect, Double Chamber Right Ventricle, Mitral Dysplasia, and others less frequent. The most represented pure breeds were Boxer, German Shepherd, French Bulldog, English Bulldog, Maltese, Newfoundland, Rottweiler, Golden Retriever, Chihuahua, and others in lower percentage. Chihuahuas, American Staffordshire Terriers, Border Collies, French Bulldogs, and Cavalier King Charles Spaniel were the most appreciated all of which showed a high value of volatility. This study found evidence for the value of the screening program implemented in Boxers; fashions and trends influence dog owners' choices more than the worries of health problems in a breed. Effective breeding programs are needed in order to control the diffusion of CHDs without impoverishing the genetic pool.Entities:
Mesh:
Year: 2020 PMID: 32716943 PMCID: PMC7384636 DOI: 10.1371/journal.pone.0230160
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of congenital heart defects of the included population.
| CHDs | TOTAL | CHDi | CHDa | MALE | FEMALE | AGE (months) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | CHDi | CHDa | TOTAL | % | CHDi | CHDa | TOTAL | % | Q2 (Q1 –Q3) | |
| 689 | 34.1 | 570 | 82.7 | 119 | 17.3 | 339 | 67 | 406 | 58.9 | 231 | 52 | 283 | 41.1 | 10 (5–24) | |
| 534 | 26.4 | 490 | 71.1 | 44 | 8.2 | 156 | 15 | 171 | 32.0 | 334 | 29 | 363 | 68.0 | 7 (3–20.5) | |
| 296 | 14.6 | 220 | 31.9 | 76 | 25.7 | 139 | 44 | 183 | 61.8 | 81 | 32 | 113 | 38.2 | 12.5 (4 31) | |
| 98 | 4.8 | 39 | 5.7 | 59 | 60.2 | 21 | 33 | 54 | 55.1 | 18 | 26 | 44 | 44.9 | 8 (4–20.5) | |
| 95 | 4.7 | 80 | 11.6 | 15 | 15.8 | 54 | 7 | 61 | 64.2 | 26 | 8 | 34 | 35.8 | 25 (10–81) | |
| 69 | 3.4 | 51 | 7.4 | 18 | 26.1 | 26 | 8 | 34 | 49.3 | 25 | 10 | 35 | 50.7 | 10 (6–28) | |
| 42 | 2.1 | 21 | 3.0 | 21 | 50.0 | 10 | 3 | 13 | 31.0 | 11 | 18 | 29 | 69.0 | 15 (7–35) | |
| 37 | 1.8 | 21 | 3.0 | 16 | 43.2 | 14 | 9 | 23 | 62.2 | 7 | 7 | 14 | 37.8 | 6 (4–11) | |
| 32 | 1.6 | 27 | 3.9 | 5 | 15.6 | 15 | 5 | 20 | 62.5 | 12 | 0 | 12 | 37.5 | 8 (4–17.5) | |
| 21 | 1.0 | 0 | 0.0 | 21 | 100.0 | 0 | 11 | 11 | 52.4 | 0 | 10 | 10 | 47.6 | 5 (3–9) | |
| 15 | 0.7 | 15 | 2.2 | 0 | 0.0 | 6 | 0 | 6 | 40.0 | 9 | 0 | 9 | 60.0 | 11 (5–29) | |
| 12 | 0.6 | 6 | 0.9 | 6 | 50.0 | 4 | 4 | 8 | 66.7 | 2 | 2 | 4 | 33.3 | 26.5 (3–76) | |
| 10 | 0.5 | 5 | 0.7 | 5 | 50.0 | 3 | 5 | 8 | 80.0 | 2 | 0 | 2 | 20.0 | 14 (2–26) | |
| 10 | 0.5 | 0 | 0.0 | 10 | 100.0 | 0 | 6 | 6 | 60.0 | 0 | 4 | 4 | 40.0 | 6.5 (4–21) | |
| 10 | 0.5 | 5 | 0.7 | 5 | 50.0 | 0 | 1 | 1 | 10.0 | 5 | 4 | 9 | 90.0 | 14 (10–47) | |
| 52 | 2.6 | 18 | 2.6 | 34 | 65.4 | 6 | 14 | 20 | 38.5 | 12 | 20 | 32 | 10 (4–54) | ||
| 2,022 | 100 | 1,568 | 454 | 793 | 232 | 1,025 | 775 | 222 | 997 | ||||||
CHDs, congenital heart diseases; CHDi, isolated congenital heart diseases; CHDa, associated congenital heart diseases; PS, pulmonic stenosis; PDA, Patent Ductus Arteriosus; SAS, Subaortic Stenosis; VSD, Ventricular Septal Defect; AS, aortic stenosis; TD, Tricuspid Dysplasia; ASD, Atrial Septal Defect; DCRV, Double Chamber Right Ventricle; MD, Mitral valve Dysplasia; TOF, Tetralogy of Fallot; rPDA, reverse Patent Ductus Arteriosus; MVS, Mitral valve Stenosis; BAV, Aortic Bicuspid Valve; PLCVC, persistent left cranial vena cava; AVCD, Atrioventricular Canal Disease
othersa CTD, Cor Triatriatum Dexter; AVF, Aortovenous Fistula; PPDH, Pericardial Peritoneum Diaphragmatic Hernia; QAV, Quadricuspid Aortic Valve; AH, Aortic Hypoplasia; AI, Aortic Insufficiency; AOr, Aortic Overriding; APW, Aortopulmonary Window; MI, Mitral Insufficiency; TVS, Tricuspid Valve Stenosis; TA, Truncus Arteriosus; CollF, Systemic to Pulmonary Arterial Collateral Flow; AC, Azygos Continuation; ACT, Anomalous Coronary Truncus.
Fig 1Average age (months) of the pure breed dogs belonging to the most represented isolated CHDs.
AS, Aortic Stenosis; ASD, Atrial Septal Defect; TD, Tricuspid Dysplasia; SAS, Subaortic Stenosis; rPDA, Reverse Patent Ductus Arteriosus; PS, Pulmonary Stenosis; PDA, Patent Ductus Arteriosus; VSD, Ventricular Septal Defect; DCRV, Double Chamber Right Ventricle; MD, Mitral Dysplasia; TOF, Tetralogy of Fallot.
Summary of the percentage distribution of CHDs in purebreeds and in crossbreeds included in this study.
| Breed | PS | PDA | SAS | AS | TD | VSD | MD | DCRV | ASD | rPDA | other CHDs
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.8 | - | 37.5 | 19.9 | 3.0 | 0.4 | 0.4 | 0.4 | 2.6 | - | 1.1 | |
| 8.5 | 65.9 | 14.0 | 3.1 | 4.7 | - | - | - | 0.8 | - | 3.1 | |
| 82.6 | 4.7 | - | 3.5 | - | 7.0 | 1.2 | 1.2 | - | - | - | |
| 88.1 | 1.5 | 1.5 | 1.5 | 4.5 | - | - | - | - | - | 3.0 | |
| 5.9 | 76.5 | - | - | - | 5.9 | 2.0 | - | - | 9.8 | - | |
| 11.9 | 42.9 | 38.1 | - | 4.8 | - | - | - | - | - | 2.4 | |
| 23.8 | 7.1 | 45.2 | 2.4 | 2.4 | - | 4.8 | 2.4 | 2.4 | - | 9.5 | |
| 29.3 | 7.3 | 31.7 | 2.4 | 14.6 | - | 4.9 | 9.8 | - | - | - | |
| 25.6 | 59.0 | - | - | - | 2.6 | - | 10.3 | - | 2.6 | - | |
| 20.0 | 65.7 | - | - | 5.7 | 2.9 | - | - | 2.9 | 2.9 | - | |
| 6.5 | 22.6 | 12.9 | - | 35.5 | 3.2 | 6.5 | - | 3.2 | 3.2 | 6.5 | |
| 40.0 | 60.0 | - | - | - | - | - | - | - | - | - | |
| 86.2 | - | - | 3.5 | - | - | 6.9 | 3.5 | - | - | - | |
| 3.5 | 89.7 | - | - | - | - | - | - | 3.5 | - | 3.5 | |
| 96.4 | 3.6 | - | - | - | - | - | - | - | - | - | |
| 59.3 | 37.0 | - | - | - | - | - | - | - | - | 3.7 | |
| 30.4 | 47.8 | - | - | - | 8.7 | 4.4 | - | 4.4 | - | 4.4 | |
| 4.6 | 59.1 | - | - | - | 18.2 | - | - | 4.6 | - | 13.6 | |
| 9.1 | 68.2 | 4.6 | - | - | 4.6 | 4.6 | - | - | - | 9.1 | |
| 4.6 | - | 72.7 | 4.6 | 9.1 | - | - | - | - | - | 9.1 | |
| - | 5.0 | 15.0 | 30.0 | 5.0 | - | 30.0 | 5.0 | - | - | 10.0 | |
| 39.3 | 36.3 | 7.5 | 3.1 | 2.4 | 4.1 | 2.0 | 2.0 | 1.0 | 1.4 | 1.0 | |
| 41.4 | 42.9 | 2.6 | 1.1 | 1.1 | 3.7 | 1.1 | 1.1 | 1.1 | 1.6 | 2.6 |
CHDs, congenital heart diseases; PS, pulmonic stenosis; PDA, Patent Ductus Arteriosus; SAS, sub-aortic stenosis; AS, aortic stenosis; TD, Tricuspid Dysplasia; VSD, Ventricular Septal Defect; MD, Mitral valve Dysplasia; DCRV, Double Chamber Right Ventricle; ASD, Atrial Septal Defect; rPDA, reverse Patent Ductus Arteriosus
a MVS, Mitral valve Stenosis; BAV, Aortic Bicuspid Valve; AVCD, Atrioventricular Canal Disease; CTD, Cor Triatriatum Dexter; AVF, Aortovenous Fistula; PPDH, Pericardial Peritoneum Diaphragmatic Hernia; QAV, Quadricuspid Aortic Valve; AH, Aortic Hypoplasia; AI, Aortic Insufficiency; AOr, Aortic Overriding; APW, Aortopulmonary Window; MI, Mitral Insufficiency; TVS, Tricuspid Valve Stenosis; TA, Truncus Arteriosus; CollF, Systemic to Pulmonary Arterial Collateral Flow; AC, Azygos Continuation; ACT, Anomalous Coronary Truncus;.
b West Highland white terrier; German Spitz; Corso Dog; Beagle; Jack Russel; Schnauzer; English setter; Pitbull; Australian Shepherd; Fox Terrier; Bernese mountain dog; Bolognese; Pembroke Welsh Corgi; Belgian shepherd; Greyhound; Shi tzu; Epagneul Breton; Pug; Swiss shepherd; Weimaraner; Akita Inu; Bichon Frisè; Bullmastiff; Great Dane; Italian Segugio; Shiba Inu; Czechoslovakian Wolfdog; Greater Swiss Mountain Dog; Neapolitan Mastiff; Pekingese dog; Pyrenean Mountain Dog; Basset hound; Bergamasco shepherd; Bobtail; Chow Chow; Dogo Argentino; Griffon Blue de Guascogne; Hungarian Bracco; Irish setter; Italian Greyhound; Italian shepherd dog; Lagotto; Maremma Sheepdog; Miniature Schnauzer; Pointer; Samoyed; Shetland Sheepdog; Welsh Terrier; Whippet; Alaskan Malamute; Appenzeller Mountain dog; Bavarian Mountain dog; Cairn Terrier; Cirneco dell'Etna; Dalmatian; Flat Coat retriever; Irish terrier; Italian Bracco; Jagd terrier; Karst shepherd; Lancashire Heeler; Magyar Agar; Norfolk terrier; Parson Russel terrier; Perro de Agua; Podenco ibicenco; Rhodesian Ridgeback; Scottish shepherd; Shar Pei; Spinone; Saint Bernard Dog.
Fig 2Probability of identifying Pulmonic Stenosis in Boxers, French Bulldogs and English Bulldogs.
Red line: Boxer; Green line: English Bulldog; Blue line: French Bulldog.
Fig 3Probability of identifying Pulmonic Stenosis in Boxers and other large breeds admitted from 1997 to 2017.
Blue line: Boxer; Orange line: other large breeds (American Staffordshire Terrier; Golden Retriever; German Shepherd; Rottweiler). P, Probability (%). X-axis: years.
Fig 4Probability of identifying Patent Ductus Arteriosus in large breeds vs German Shepherd admitted from 1997 to 2017.
Blue line: German Shepherd; Red line: other large breeds (Bull Terrier; Dobermann; Golden Retriever; Labrador Retriever; Newfoundland; Rottweiler). P, Probability (%). X-axis: years.
Summary of CHDs associations in the included population.
| CHDa | N | % | |
|---|---|---|---|
| PS | SAS | 35 | 22.29 |
| PS | VSD | 30 | 19.11 |
| PS | PDA | 13 | 8.28 |
| PS | Other CHDs | 15 | 9.55 |
| SAS | PDA | 13 | 8.28 |
| SAS | VSD | 5 | 3.18 |
| SAS | other CHDs
| 10 | 6.37 |
| VSD | DCRV | 7 | 4.46 |
| VSD | other CHDs
| 6 | 3.82 |
| ASD | AVCD | 5 | 3.18 |
| other combinations | 18 | 11.46 | |
CHDa, associated congenital heart diseases; CHDs, congenital heart diseases, PS, pulmonic stenosis; VSD, Ventricular Septal Defect; PDA, Patent Ductus Arteriosus.
a DCRV, Double Chamber Right Ventricle; AS, aortic stenosis; ASD, Atrial Septal Defect; TD, tricuspid valve dysplasia; AVF, aortovenosus fistula; PLCVC, persistent left atrial vena cava; TVS, Tricuspid Valve Stenosis.
b TD, tricuspid valve dysplasia; MD, Mitral valve Dysplasia; MVS, Mitral valve Stenosis; BAV, bicuspid aortic valve; PLCVC, persistent left atrial vena cava; QAV, Quadricuspid Aortic Valve; TOF, Tetralogy of Fallot
c PDA, Patent Ductus Arteriosus; ASD, Atrial Septal Defect; MD, Mitral valve Dysplasia; AOr, Aortic Overriding.
d ASD-AS, Atrial Septal Defect–Aortic Stenosis; ASD-TD, Atrial Septal Defect–Tricuspid Dysplasia; ASD–AVCD, atrial septal defect-atrioventricular canal defects; PDA-AS, Patent Ductus Arteriosus—Aortic Stenosis; PDA–ASD, Patent Ductus Arteriosus-atrial septal defect; PDA–TD, Patent Ductus Arteriosus-Tricuspid Dysplasia; PDA–MVS, Patent Ductus Arteriosus-Mitral valve Stenosis; PDA–AVF, Patent Ductus Arteriosus- aortovenosus fistula; TD–DCRV, Tricuspid Dysplasia—Double Chamber Right Ventricle; TD–AS, Tricuspid Dysplasia–atrial septal defect TD–CTD, Tricuspid Dysplasia- Cor Triatriatum Dexter; TOF–APW, Tetralogy of Fallot-Aortopulmonary Window; AS–BAV, Aortic Stenosis-bicuspid aortic valve; DCRV—HCM; MVS–TVS, Mitral valve Stenosis- Tricuspid Valve Stenosis.
Summary of the distribution of CHDs by sex in purebreeds.
| CHDs | N | Frequency | 95% CI | Male frequency | Female frequency | p-value |
|---|---|---|---|---|---|---|
| 491 | 35.66 | 33.13–38.19 | 41.17 | 29.64 | <0.0001 | |
| 408 | 29.63 | 27.22–32.04 | 19.47 | 40.73 | <0.0001 | |
| 213 | 15.47 | 13.56–17.38 | 18.64 | 12.01 | 0.001 | |
| 80 | 5.81 | 4.57–7.05 | 7.51 | 3.95 | 0.005 | |
| 49 | 3.56 | 2.58–4.54 | 3.48 | 3.65 | 0.86 | |
| 32 | 2.32 | 1.53–3.12 | 2.50 | 2.13 | 0.64 | |
| 25 | 1.82 | 1.11–2.52 | 1.95 | 1.67 | 0.70 | |
| 19 | 1.38 | 0.76–2.00 | 1.81 | 0.91 | 0.15 | |
| 17 | 1.23 | 0.65–1.82 | 1.25 | 1.22 | 0.95 | |
| 12 | 0.87 | 0.38–1.36 | 0.56 | 1.22 | 0.19 | |
| 31 | 2.25 | 1.47–3.04 | 1.67 | 2.89 | 0. 48 |
CHDs, congenital heart diseases; PS, pulmonic stenosis; PDA; Patent Ductus Arteriosus; SAS, SubAortic Stenosis; AS, Aortic Stenosis; TD, Tricuspid Dysplasia; VSD, Ventricular Septal Defect; MD, mitral dysplasia; DCRV, Double Chamber Right Ventricle; ASD, atrial septal defect; rPDA, reverse Patent Ductus Arteriosus.
a MVS, Mitral valve Stenosis; BAV, Aortic Bicuspid Valve; AVCD, Atrioventricular Canal Disease; CTD, Cor Triatriatum Dexter; AVF, Aortovenous Fistula; PPDH, Pericardial Peritoneum Diaphragmatic Hernia; QAV, Quadricuspid Aortic Valve; AH, Aortic Hypoplasia; AI, Aortic Insufficiency; AOr, Aortic Overriding; APW, Aortopulmonary Window; MI, Mitral Insufficiency; TVS, Tricuspid Valve Stenosis; TA, truncus arteriosus; CollF, Systemic to Pulmonary Arterial Collateral Flow; AC, Azygos Continuation; ACT, Anomalous Coronary Truncus.
Summary of the distribution of the CHDs by sex in crossbreeds.
| CHDs | N | Frequency | 95% CI | Male frequency | Female frequency | p-value |
|---|---|---|---|---|---|---|
| 82 | 42.93 | 40.32–45.55 | 21.62 | 56.41 | < .0001 | |
| 79 | 41.36 | 38.76–43.96 | 58.11 | 30.77 | <0.0002 | |
| 30 | 15.71 | 13.79–17.63 | 20.27 | 12.82 | 0.17 |
CHDs, congenital heart diseases; PDA, Patent Ductus Arteriosus; PS, Pulmonic Stenosis
a VSD, Ventricular Septal Defect; SAS, Subaortic Stenosis; rPDA, reverse Patent Ductus Arteriosus; AS, Aortic Stenosis; ASD, Atrial Septal Defect; DCRV, Double Chamber Right Ventricle; MD, Mitral valve Dysplasia; TD, tricuspid valve dysplasia; AVCD, Atrioventricular Canal Disease; AVCDp, partial Atrioventricular Canal Disease; AVF, aortovenus fistula.
Fig 5Associated congenital heart defects admitted from 1997 to 2017.
PS, pulmonic stenosis; SAS, Subaortic Stenosis; VSD, Ventricular Septal Defect; PDA, Patent Ductus Arteriosus; DCRV, Double Chamber Right Ventricle; ASD, Atrial Septal Defect; AVCD, Atrioventricular Canal Disease.
Summary of CHDi, OR referred to overall CHD (with 95% confidence interval), popularity, and volatility in each breed.
| Breed | CHDi | OR | p value | ti | vi |
|---|---|---|---|---|---|
| 6 | 0.90 (0.65–1.24) | 0.593 | 51457 | 13 | |
| 6 | 0.89 (0.61–1.28) | 0.6586 | 38859 | 11 | |
| 7 | 0.70 (0.46–1.07) | 0.120 | 36973 | 11 | |
| 10 | 6.98 (5.60–8.71) | 0.000 | 15855 | 10 | |
| 3 | 2.29 (1.59–3.29) | 0.000 | 15904 | 9 | |
| 10 | 0.55 (0.40–0.75) | 0.000 | 86696 | 7 | |
| 12 | 2.74 (2.14–3.51) | 0.000 | 30417 | 6 | |
| 10 | 0.22 (0.15–0.31) | 0.000 | 154498 | 4 | |
| 7 | 0.53 (0.34–0.80) | 0.001 | 49035 | 4 | |
| 5 | 5.60 (3.84–8.15) | 0.000 | 6127 | 3 | |
| 5 | 0.84 (0.57–1.23) | 0.419 | 38247 | 2 | |
| 7 | 2.02 (1.33–3.09) | 0.003 | 13130 | 2 | |
| 5 | 2.30 (1.74–3.05) | 0.000 | 27179 | 2 | |
| 6 | 1.18 (0.84–1.65) | 0.352 | 35703 | 0 | |
| 8 | 1.61 (1.03–2.50) | 0.045 | 14974 | -2 | |
| 13 | 0.32 (0.26–0.38) | 0.000 | 386970 | -3 | |
| 15 | 0.52 (0.38–0.70) | 0.000 | 93858 | -4 | |
| 14 | 4.01 (3.50–4.61) | 0.000 | 97670 | -4 | |
| 4 | 0.66 (0.46–0.96) | 0.029 | 51524 | -7 | |
| 7 | 2.88 (2.11–3.92) | 0.000 | 17924 | -10 | |
| 6 | 0.94 (0.62–1.42) | 0.918 | 29099 | -10 |
CHDi, isolated congenital heart diseases; ti, popularity; vi, volatility.